TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23757426

Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing (IS) strategy
Number of subjects: 2159

Group type: COMPARATOR
Intervention: Insulin-providing (IP) strategy
Number of subjects: 2159

Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing (IS) strategy in men
Number of subjects: 2159
Study: 21691934

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) applied during intubation
Number of subjects: 50

Group type: COMPARATOR
Intervention: No cricoid pressure (CP) applied during intubation
Number of subjects: 50
Study: 19344441

Group type: EXPERIMENTAL
Intervention: Recovery Management Checkup (RMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 17356308

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 28
Study: 15331896

Group type: EXPERIMENTAL
Intervention: Doxazosin (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Terazosin (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Switching drugs after no improvement
Number of subjects: 50
Study: 11422094

Group type: EXPERIMENTAL
Intervention: 300 mg acetylsalicyclic acid (ASA)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 270
Study: 9153098

Group type: EXPERIMENTAL
Intervention: Cefixime plus betamethasone (n = 59)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cefixime (n = 61)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 142
Study: 8125421

Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (intravenous streptokinase)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Captopril 3 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Captopril (doses not specified)
Number of subjects: 300
Study: 3337794

Group type: EXPERIMENTAL
Intervention: Morphine 100 micrograms kg‐1
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Morphine 50 micrograms kg‐1
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Buprenorphine 3.0 micrograms kg‐1
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Buprenorphine 1.5 micrograms kg‐1
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Morphine and Buprenorphine (both dosages)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Buprenorphine and Morphine
Number of subjects: 57
Study: 29569806

Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m2/day in EXIST-1, titrated to trough 5-15 ng/mL; 10 mg/day in EXIST-2)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 212
Study: 26938860

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment for acne vulgaris for 6 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no isotretinoin treatment)
Number of subjects: 88
Study: 23848184

Group type: EXPERIMENTAL
Intervention: 25 g intravenous albumin for the first 3 days within the first week of ICU stay (group A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No albumin treatment (group B)
Number of subjects: 21
Study: 23911171

Group type: EXPERIMENTAL
Intervention: Wireless meters
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nonwireless meters
Number of subjects: 47
Study: 21942435

Group type: EXPERIMENTAL
Intervention: High-dose hydrocortisone (0.45 mg/kg IV)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Moderate-dose hydrocortisone (0.15 mg/kg IV)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 18450517

Group type: EXPERIMENTAL
Intervention: Tarenflurbil 800 mg twice per day
Number of subjects: 210

Group type: COMPARATOR
Intervention: Tarenflurbil 800 mg twice per day for 24 months
Number of subjects: 210
Study: 22305824

Group type: EXPERIMENTAL
Intervention: Trapeziectomy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with palmaris longus interposition
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction and tendon interposition
Number of subjects: 174
Study: 15829988

Group type: EXPERIMENTAL
Intervention: Vardenafil (PDE-5 inhibitor)
Number of subjects: 0
Study: 12873331

Group type: EXPERIMENTAL
Intervention: Clonazepam detoxification (CDTX)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clonazepam maintenance treatment (CMT)
Number of subjects: 66
Study: 9814449

Group type: EXPERIMENTAL
Intervention: Deflazacort (DEFLA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prednisone (PRED)
Number of subjects: 24
Study: 8595686

Group type: COMPARATOR
Intervention: Lidocaine 2% (40 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thiopentone 2.5% (50 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 90
Study: 2574045

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior high blood pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response to therapy
Number of subjects: 0
Study: 1207275

Group type: EXPERIMENTAL
Intervention: Arginine infusion of 0.5 g/kg over 30 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arginine infusion
Number of subjects: 0
Study: 29636011

Group type: EXPERIMENTAL
Intervention: Hydromorphone IV-PCA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sufentanil IV-PCA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both hydromorphone and sufentanil IV-PCA
Number of subjects: 80
Study: 29231540

Group type: EXPERIMENTAL
Intervention: Combination group (acupuncture at GV and Jiaji combined with rehabilitation training)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture group (simple acupuncture)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rehabilitation group (simple rehabilitation training)
Number of subjects: 90
Study: 26178815

Group type: EXPERIMENTAL
Intervention: Sumatriptan TDS
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo TDS
Number of subjects: 239
Study: 23132445

Group type: EXPERIMENTAL
Intervention: Omega-3 oral nutritional supplements (TheraTears Nutrition for Dry Eyes)
Number of subjects: 18
Study: 21240001

Group type: EXPERIMENTAL
Intervention: Computer protocol (CP)
Number of subjects: 18
Study: 18380771

Group type: EXPERIMENTAL
Intervention: Warming group (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study: 16937747

Group type: EXPERIMENTAL
Intervention: Tidal breathing method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dosimeter method
Number of subjects: 30
Study: 14620923

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg daily)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Other antihypertensive agents (control)
Number of subjects: 132
Study: 10906645

Group type: EXPERIMENTAL
Intervention: 10% glycolic acid gel, pH 3.52, applied once daily for 7 days and then twice daily for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo gel, pH 5.75
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10% glycolic acid gel, pH 3.52
Number of subjects: 12
Study: 8630662

Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil (PHSO diet)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Butter diet
Number of subjects: 31

Group type: COMPARATOR
Intervention: Partially hydrogenated fish oil (PHFO diet)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 31
Study: 1427582

Group type: EXPERIMENTAL
Intervention: Amikacin once daily plus metronidazole
Number of subjects: 325

Group type: COMPARATOR
Intervention: Amikacin twice daily plus metronidazole
Number of subjects: 325
Study: 6565300

Group type: EXPERIMENTAL
Intervention: Drug information only
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Side-effect management techniques (SEMT) information
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined drug and SEMT information
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 31980334

Group type: EXPERIMENTAL
Intervention: Video and brochure intervention
Number of subjects: 551

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Intention to give blood (after intervention)
Number of subjects: 551
Study: 28993286

Group type: EXPERIMENTAL
Intervention: SPIRIT intervention delivered by trained research nurses
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: SPIRIT intervention for surrogates
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care plus delayed SPIRIT implementation
Number of subjects: 400
Study: 27757142

Group type: EXPERIMENTAL
Intervention: Therapeutic educational program in oral health (TEPOH)
Number of subjects: 230

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 230
Study: 25634936

Group type: EXPERIMENTAL
Intervention: Arm A (SFI only)
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Arm B (SFI plus reminders)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Arm C (control group)
Number of subjects: 781
Study: 24209657

Group type: EXPERIMENTAL
Intervention: Mass practice (3 training blocks of 15 minutes each with a 5-minute break)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Similar exercise (laparoscopic bean transfer)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dissimilar exercise (open suturing)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rest
Number of subjects: 75
Study: 21911720

Group type: COMPARATOR
Intervention: Clonidine 0.1 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Venlafaxine 75 mg
Number of subjects: 102
Study: 19099860

Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride and oral rehydration salt treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral rehydration salt treatment only
Number of subjects: 55
Study: 16317760

Group type: COMPARATOR
Intervention: IV EPO 600 IU/kg (max dose 40,000 IU) or placebo once weekly for 16 weeks, increased to 900 IU/kg (max dose 60,000 IU) if no response by week 3 or 4
Number of subjects: 12
Study: 15048616

Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg b.i.d. for 14 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11868136

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (two 45-min sessions)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no information on OSAHS or CPAP)
Number of subjects: 12
Study: 9140705

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 6
Study: 7957792

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU, single oral dose)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 174
Study: 2958383

Group type: EXPERIMENTAL
Intervention: CT directed biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic directed biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blind percutaneous liver biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative CT directed biopsy
Number of subjects: 0
Study: 29674251

Group type: EXPERIMENTAL
Intervention: NTX + BUP
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: NTX + placebo BUP (PBO-B)
Number of subjects: 378

Group type: COMPARATOR
Intervention: placebo NTX (PBO-N) + placebo BUP (PBO-B)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: NTX/BUP
Number of subjects: 378
Study: 27984490

Group type: EXPERIMENTAL
Intervention: Pain Course (Internet-delivered cognitive behavioural pain management course)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 30
Study: 26014940

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 23951825

Group type: EXPERIMENTAL
Intervention: Elonza (generic product of sildenafil) 100 mg taken as needed
Number of subjects: 210
Study: 21914162

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (5 cups per day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (5 cups per day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No coffee (water)
Number of subjects: 45
Study: 18979392

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dilapan and sulprostone
Number of subjects: 16
Study: 16239897

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 14
Study: 12698929

Group type: EXPERIMENTAL
Intervention: Educational intervention in the clinic waiting room
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual clinic care (no structured education during the waiting time in the clinic)
Number of subjects: 320
Study: 10636375

Group type: EXPERIMENTAL
Intervention: Maternal oral zidovudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7488485

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thiopentone 6 mg kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 1827966

Group type: EXPERIMENTAL
Intervention: 16 mg oral ondansetron
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 7302464

Group type: EXPERIMENTAL
Intervention: 10 mg of sodium aurothiomalate weekly
Number of subjects: 60

Group type: COMPARATOR
Intervention: 50 mg of sodium aurothiomalate weekly
Number of subjects: 60
Study: 29686285

Group type: EXPERIMENTAL
Intervention: Plasma proteins in children with small head circumference at birth
Number of subjects: 500

Group type: COMPARATOR
Intervention: Plasma proteins in children with normal head circumference at birth
Number of subjects: 500
Study: 27698559

Group type: EXPERIMENTAL
Intervention: TURP plus tamsulosin hydrochloride 0.2 mg (TAM)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: TURP plus tamsulosin hydrochloride 0.2 mg (TAM) plus solifenacin succinate 5 mg (SOL)
Number of subjects: 116

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 116
Study: 25936812

Group type: EXPERIMENTAL
Intervention: Processed Ultra Emu Oil
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (cottonseed oil)
Number of subjects: 45
Study: 23254226

Group type: EXPERIMENTAL
Intervention: Revised scoring approach using a 4-point Likert response set
Number of subjects: 343

Group type: COMPARATOR
Intervention: Original FTND scoring with forced-choice response format
Number of subjects: 343
Study: 19875376

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control
Number of subjects: 83
Study: 18209516

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16337504

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day for 12 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day for 3 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Lipid-lowering diet for 3 months
Number of subjects: 43
Study: 14620649

Group type: COMPARATOR
Intervention: Counseling-only control group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nicotine patch/bupropion group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nicotine patch group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Bupropion group
Number of subjects: 140
Study: 10354218

Group type: EXPERIMENTAL
Intervention: 0.4 mg of TNF-alpha plus 1 mg kg-1 melphalan (IHPTM group)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 1 mg kg-1 melphalan (IHPM group)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both groups (IHPTM and IHPM)
Number of subjects: 9
Study: 8877260

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 950

Group type: COMPARATOR
Intervention: Moderate blood pressure control
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (nisoldipine)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 950
Study: 1757024

Group type: EXPERIMENTAL
Intervention: 2 mg cefamandol administered intraocularly at the end of the operation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo administered intraocularly at the end of the operation
Number of subjects: 61
Study: 7113575

Group type: EXPERIMENTAL
Intervention: Chlorpropamide administration (CPAF test)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo administration instead of chlorpropamide
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Non flushers and aspecific flushers
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Blood pressure, serum lipids and hemostatic parameters
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Flushers
Number of subjects: 108
Study: 3893308

Group type: EXPERIMENTAL
Intervention: Proximate stapler
Number of subjects: 16

Group type: COMPARATOR
Intervention: Monofilament nylon sutures
Number of subjects: 16
Study: 30547820

Group type: EXPERIMENTAL
Intervention: Low-dose stavudine (20 mg twice daily)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Tenofovir in combination with efavirenz and lamivudine
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Both groups (stavudine and tenofovir)
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Low-dose stavudine
Number of subjects: 1067
Study: 26126817

Group type: EXPERIMENTAL
Intervention: Inpatient palliative care (PC) visits
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Palliative care actions
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Palliative care for inpatients with HF
Number of subjects: 101
Study: 24898574

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the left temporal cortex
Number of subjects: 116
Study: 22269100

Group type: EXPERIMENTAL
Intervention: Compression First (CF) strategy
Number of subjects: 289

Group type: COMPARATOR
Intervention: Analyze First (AF) strategy
Number of subjects: 289
Study: 20394471

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg QD for 3 weeks
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg QD for 2 weeks
Number of subjects: 241

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg QD for 4 weeks
Number of subjects: 241
Study: 18065503

Group type: EXPERIMENTAL
Intervention: Protected CAS (with distal filter devices)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Unprotected CAS (without distal filter devices)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Protected CAS in symptomatic patients
Number of subjects: 243

Group type: COMPARATOR
Intervention: Unprotected CAS in symptomatic patients
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Protected CAS in patients aged 75 or younger
Number of subjects: 243

Group type: COMPARATOR
Intervention: Unprotected CAS in patients aged 75 or younger
Number of subjects: 243
Study: 15515151

Group type: EXPERIMENTAL
Intervention: Kendall's taub as a summary measure of within-participant trends in adverse events
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated measures ANOVA using mixed models
Number of subjects: 0
Study: 12456424

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10628192

Group type: EXPERIMENTAL
Intervention: Enteric-coated pancreatin (25,000 U lipase; 3 x 1 caps/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 8834645

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nondialyzed uremic men
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy men
Number of subjects: 32
Study: 2327823

Group type: EXPERIMENTAL
Intervention: AIH with native semen (N, n = 68)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: AIH with washed sperm (V, n = 50)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: AIH with semen mixed with kallikrein (K, 5 IE/ml semen, n = 45)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: In vitro studies with K added semen
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Capillary tube test (CTT) with wives' cervical mucus
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Capillary tube test (CTT) with donors' cervical mucus
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Overall AIH program
Number of subjects: 172
Study: 7017582

Group type: EXPERIMENTAL
Intervention: RA 27/3 rubella vaccine
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella (RA 27/3) vaccine
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Combination vaccine incorporating HPV-77:DE-5 rubella
Number of subjects: 502

Group type: COMPARATOR
Intervention: Measles-mumps-rubella vaccines
Number of subjects: 502
Study: 30744589

Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil Mediterranean diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without nutritional intervention
Number of subjects: 0
Study: 28937894

Group type: EXPERIMENTAL
Intervention: PTFE tape
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cotton
Number of subjects: 17
Study: 27209155

Group type: EXPERIMENTAL
Intervention: Visual interruptions comprised of spatial, driving unrelated tasks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Visual interruptions comprised of non-spatial, driving unrelated tasks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Visual interruptions with no tasks added
Number of subjects: 56

Group type: COMPARATOR
Intervention: No visual interruptions (control group)
Number of subjects: 56
Study: 24440167

Group type: EXPERIMENTAL
Intervention: BIIL 284 BS
Number of subjects: 420
Study: 22077192

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Number of subjects: 15526

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 15526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15526